4-哌啶羧酸乙酯盐酸盐 | 147636-76-8

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-哌啶羧酸乙酯盐酸盐
• 中文别名: 4-哌啶甲酸乙酯盐酸盐
• 英文名称: piperidine-4-carboxylic acid ethyl ester hydrochloride
• 英文别名: ethyl piperidine-4-carboxylate hydrochloride；4-piperidinecarboxylic acid ethyl ester hydrochloride；ethyl piperidine-4-carboxylate;hydrochloride
• CAS: 147636-76-8
• 化学式: C₈H₁₅NO₂*ClH
• 分子量: 193.674
• InChiKey: SNZAKTXWTXRXNI-UHFFFAOYSA-N

物化性质

• 熔点：
  140-142°C

计算性质

• 辛醇/水分配系数(LogP)：
  0.97
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  38.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl piperidine-4-carboxylate, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl piperidine-4-carboxylate, HCl
CAS number: 147636-76-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H16ClNO2
Molecular weight: 193.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-哌啶羧酸乙酯盐酸盐 在 盐酸 、 lithium aluminium tetrahydride 、 碳酸氢钠 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 30.25h， 生成 4-(羟甲基)哌啶-1-腈
  参考文献：
  名称：

  NOVEL COMPOUNDS AS GPR119 AGONISTS

  摘要：

  本发明涉及式(I)的新化合物作为GPR119激动剂，包含此类化合物的组合物及其制备方法。

  公开号：

  US20170291910A1
• 作为产物：
  描述：

  N-Boc-4-哌啶甲酸乙酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以99%的产率得到4-哌啶羧酸乙酯盐酸盐
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
  [FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET

  摘要：

  本文提供了Formula I的化合物：(I)或其药用可接受的盐或溶剂，其中A、B、X1、X2、X3、X4、环D、E、Ra、Rb、n和m的含义如规范中所述，它们是RET激酶的抑制剂，并且在治疗和预防可以用RET激酶抑制剂治疗的疾病中非常有用，包括与RET相关的疾病和紊乱。

  公开号：

  WO2018071454A1

文献信息

• 一种制备普卡必利中间体的新工艺
  申请人：江苏威凯尔医药科技有限公司

  公开号：CN106146386A

  公开（公告）日：2016-11-23

  本发明公开了一种式(I)所示的1‑(3‑甲氧丙基)‑4‑哌啶胺的制备方法，其包括如下列步骤：(1)将式(II)化合物在氨的溶液中反应制得式(III)化合物；(2)将式(III)化合物与1，3‑二溴‑5，5‑二甲基海因在碱性条件下反应制得式(I)化合物。本制备方法无特殊反应设备要求，操作简便，适于工业化生产；收率高，三废少，成本低；产品化学纯度高，无重金属残留问题。
• [EN] S1P MODULATING AGENTS<br/>[FR] AGENTS MODULATEURS DE S1P
  申请人：BIOGEN IDEC INC

  公开号：WO2014120764A1

  公开（公告）日：2014-08-07

  Compounds of formula (I) can modulate the activity of one or more S 1P receptors. Sphingosine 1-phosphate (S IP) is a lysophospholipid mediator that evokes a variety of cellular responses by stimulation of five members of the endothelial cell differentiation gene (EDG) receptor family, namely S1P1, S1P2, S1P3, S1P4, and S1P5 (formerly EDG1, EDG5, EDG3, EDG6 and EDG8). The EDG receptors are G-protein coupled receptors (GPCRs) and on stimulation propagate second messenger signals via activation of heterotrimeric G-protein alpha (Ga.) subunits and beta-gamma (G()y) dimers.

  化合物的化学式（I）可以调节一个或多个S1P受体的活性。神经鞘氨醇1-磷酸（S1P）是一种溶酶磷脂介质，通过刺激内皮细胞分化基因（EDG）受体家族的五个成员，即S1P1、S1P2、S1P3、S1P4和S1P5（以前称为EDG1、EDG5、EDG3、EDG6和EDG8），引发各种细胞反应。EDG受体是G蛋白偶联受体（GPCRs），在受到刺激时通过激活异源三聚体G蛋白α（Ga.）亚基和β-γ（Gβγ）二聚体传递第二信使信号。
• Aldehyde derivatives and their use as calpain inhibitors
  申请人：FUJIREBIO Inc.

  公开号：EP0520336A3

  公开（公告）日：1993-04-07

  Aldehyde derivatives with a specific calpain inhibiting activity and a platelet-aggregation inhibiting effect with formula (I) or formula (II): wherein R1 represents an aromatic hydrocarbon group, a heterocyclic group, or a group of -X-R3 in which X represents O, -S(O)m- (m = 0, 1, or 2), and R3 represents an aromatic hydrocarbon group, a heterocyclic group, or an alkyl group; Z represents R4-Y- or R60-CH(R5)- in which Y represents a 3- to 7-membered nitrogen-containing saturated heterocyclic group, or a single cyclic saturated hydrocarbon group, R4 represents an alkyl group, an alkenyl group, an alkynyl group, an acyl group, a sulfonyl group, an alkoxycarbonyl group, a carbamoyl group, or a thiocarbamoyl group, R5 represents hydrogen, an alkyl group, or an aromatic hydrocarbon group, and R6 represents an acyl group, a carbamoyl group, a thiocarbamoyl group, or an alkyl group; and n is an integer of 1 to 5. wherein R7, R8, R9, and R10 are defined in the specification.

  醛衍生物具有特定的钙蛋白酶抑制活性和抑制血小板聚集作用，其化学式为（I）或化学式（II）： 其中，R1代表芳香烃基、杂环基，或-X-R3基团，其中X代表O、-S(O)m-（m = 0、1或2），R3代表芳香烃基、杂环基或烷基；Z代表R4-Y-或R60-CH(R5)-，其中Y代表3-至7-成员含氮饱和杂环基，或单环饱和碳氢基团，R4代表烷基、烯基、炔基、酰基、磺酰基、烷氧羰基、氨基甲酰基或硫代氨基甲酰基，R5代表氢、烷基或芳香烃基，R6代表酰基、氨基甲酰基、硫代氨基甲酰基或烷基；n为1至5的整数。 其中，R7、R8、R9和R10在说明书中有定义。
• Synthesis of GABA_A Receptor Agonists and Evaluation of their α-Subunit Selectivity and Orientation in the GABA Binding Site
  作者：Michaela Jansen、Holger Rabe、Axelle Strehle、Sandra Dieler、Fabian Debus、Gerd Dannhardt、Myles H. Akabas、Hartmut Lüddens

  DOI：10.1021/jm701562x

  日期：2008.8.1

  heterologously expressed GABA A alpha ibeta 3gamma 2 receptors (i = 1-6). The effects of 5-aminomethyl-3 H-[1,3,4]oxadiazol-2-one 5d were comparable to GABA for all alpha subunit isoforms. 5-piperidin-4-yl-3 H-[1,3,4]oxadiazol-2-one 5a and 5-piperidin-4-yl-3 H-[1,3,4]oxadiazol-2-thione 6a were weak agonists at alpha 2-, alpha 3-, and alpha 5-containing receptors. When coapplied with GABA, they were antagonistic

  用于治疗各种疾病的药物靶向 GABA A 受体。为了开发 α 亚基选择性化合物，我们合成了 5-(4-哌啶基)-3-异恶唑醇 (4-PIOL) 衍生物。3-isoxazolol 部分被 1,3,5-oxadiazol-2-one、1,3,5-oxadiazol-2-thione 和取代的 1,2,4-triazol-3-ol 杂环取代碱性哌啶取代基以及不含碱性氮的取代基。通过 [(3) H] muscimol 绑定和膜片钳实验与异源表达 GABA A α ibeta 3gamma 2 受体 (i = 1-6) 筛选化合物。5-aminomethyl-3 H-[1,3,4]oxadiazol-2-one 5d 的作用与 GABA 对所有 α 亚基亚型的影响相当。5-哌啶-4-基-3 H-[1,3,4]恶二唑-2-one 5a和5-哌啶-4-yl-3 H-[1,3,4]恶二唑-2-硫酮6a分别为α
• 2-Benzoyl-2-ethoxycarbonylvinyl-1 and 2-benzoylamino-2-methoxy-carbonylvinyl-1 as<i>N</i>-protecting groups in peptide synthesis. Their application in the synthesis of dehydropeptide derivatives containing<i>N</i>-terminal 3-heteroarylamino-2,3-dehydroalanine
  作者：Jurij Svete、Mateja Aljaž-Rožič、Branko Stanovnik

  DOI：10.1002/jhet.5570340128

  日期：1997.1

  and 2-benzoylamino-2-methoxycarbonylvinyl groups in the peptide synthesis. Reactions of ethyl 2-benzoyl-3-dimethylaminopropenoate (6) with α-amino acids gave N-(2-benzoyl-2-ethoxycarbonylvinyl-1)-α-amino acids 13–19. These were coupled with various amino acid esters to form N-(2-benzoyl-2-ethoxycar-bonylvinyl-1)-protected dipeptide esters 20–31. The removal of 2-benzoyl-2-ethoxycarbonylvinyl-1 group

  2-苯甲酰基-3-二甲基氨基丙酸乙酯（6）和2-苯甲酰基氨基-3-二甲基氨基丙酸甲酯（46）被用作保护2-苯甲酰基-2-乙氧基羰基乙烯基-1和2-苯甲酰基氨基-2的氨基的试剂。肽合成中的-甲氧基羰基乙烯基。2-苯甲酰基-3-二甲基氨基丙酸乙酯（6）与α-氨基酸的反应得到N-（2-苯甲酰基-2-乙氧基羰基乙烯基-1）-α-氨基酸13-19。将它们与各种氨基酸酯偶联，形成N-（2-苯甲酰基-2-乙氧基羰基-乙烯基-1）保护的二肽酯20-31。通过肼一盐酸盐或羟胺盐酸盐去除2-苯甲酰基-2-乙氧基羰基乙烯基-1基团，可以高收率得到二肽酯32-41的氢氯化物。类似地，用甘氨酸取代2-苯甲酰基氨基-3-二甲基氨基丙酸甲酯（46）中的二甲基氨基得到N-（2-苯甲酰基氨基-2-甲氧基碳原子-乙烯基-1）甘氨酸（47），其与甘氨酸乙酯偶联得到N- [ N-（2-苯甲酰基氨基-2-甲氧基羰基乙烯基-1）甘氨酰]甘氨酸乙酯（48）。用2-氨基-4